Anti-Human ACVRL1 Antibody (SAA0129)

Catalog No.

FHE20510

Species reactivity

Human

Host species

Human

Isotype

IgG2, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Serine/threonine-protein kinase receptor R3, ACVRL1, Activin receptor-like kinase 1, ALK-1, ACVRLK1, ALK1, SKR3, TGF-B superfamily receptor type I, TSR-I

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P37023

Applications

FCM, Neutralization, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0129

Potential and emerging therapeutics for HHT., PMID:39644056

Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice., PMID:39196046

[Hereditary hemorrhagic telangiectasia]., PMID:37062633

The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH., PMID:34818449

[Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia]., PMID:34010995

Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding., PMID:32517280

ALK-1-positive inflammatory myofibroblastic tumor of the thyroid complicated by Hashimoto's thyroiditis: report of a rare case and a literature review., PMID:32430041

Endoglin: Beyond the Endothelium., PMID:32059544

Future treatments for hereditary hemorrhagic telangiectasia., PMID:31910860

Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis., PMID:31622214

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)., PMID:31444620

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma., PMID:30951193

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia., PMID:30717761

Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension., PMID:30636542

Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2., PMID:30571259

A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma., PMID:30352941

Activation of Ras in the Vascular Endothelium Induces Brain Vascular Malformations and Hemorrhagic Stroke., PMID:30208313

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study., PMID:29636300

Molecular Imaging in Cancer Drug Development., PMID:29371402

Transforming growth factor-β stimulates Smad1/5 signaling in pulmonary artery smooth muscle cells and fibroblasts of the newborn mouse through ALK1., PMID:28642261

Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia., PMID:28339142

Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis., PMID:28133920

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma., PMID:28031424

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection., PMID:27535973

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck., PMID:27648727

Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function., PMID:27528762

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma., PMID:27329247

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma., PMID:27248821

A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors., PMID:27075560

Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains., PMID:26677222

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors., PMID:26655846

Formation of vascular network structures within cardiac cell sheets from mouse embryonic stem cells., PMID:31245454

Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., PMID:26373572

Activin receptor inhibitors--dalantercept., PMID:25708802

[Bevacizumab: a new success in hereditary hemorrhagic telangiectasia]., PMID:25595875

TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets., PMID:25279424

Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis., PMID:25070888

ALK1 heterozygosity increases extracellular matrix protein expression, proliferation and migration in fibroblasts., PMID:24594380

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial., PMID:24566706

ALK1 as a novel therapeutic target for CD30⁺ T-anaplastic large cell lymphoma., PMID:24491304

A functional genomic approach reveals the transcriptional role of EDD in the expression and function of angiogenesis regulator ACVRL1., PMID:24189493

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer., PMID:24173543

Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment., PMID:24061911

Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy., PMID:24053899

SnoN facilitates ALK1-Smad1/5 signaling during embryonic angiogenesis., PMID:24019535

Activin Receptor-like kinase 1: a novel anti-angiogenesis target from TGF-β family., PMID:23815578

Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development., PMID:23812757

Molecular pathways in head and neck cancer: EGFR, PI3K, and more., PMID:23714515

Anaplastic lymphoma kinase (ALK1) immunohistochemistry in diagnostic dermatopathology; an update., PMID:23689691

[Anti-VEGF: a new therapeutic option in hereditary hemorrhagic telangiectasia]., PMID:23428664

Document Download

Anti-Human ACVRL1 Antibody (SAA0129).pdf